<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article43</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/RACE_II" style="display:block; margin-bottom:10px;">RACE II Original</a></li>
<h2><strong>RACE II</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Lenient vs Strict Rate Control in Patients with Atrial Fibrillation". The New England Journal of Medicine. 2010. 362:1363-1373. PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with permanent atrial fibrillation, is lenient rate control inferior to strict rate control for preventing cardiovascular morbidity and mortality?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with permanent atrial fibrillation, lenient rate control was not inferior to strict rate control for the prevention of cardiovascular morbidity and mortality and was easier to achieve.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Current guidelines recommend a heart rate of &lt;110 beats per minute in asymptomatic patients with permanent atrial fibrillation without the need for strict rate control unless the patient has symptoms.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, randomized, open-label, noninferiority trial.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
N=614 patients with permanent atrial fibrillation.<br/>
<br/>
Inclusion Criteria<br/>
Permanent atrial fibrillation up to 12 months, age ≤80 years, mean resting heart rate &gt;80 beats per minute, and use of oral anticoagulation therapy.<br/>
<br/>
Exclusion Criteria<br/>
Disclosed previously by the study.<br/>
<br/>
Baseline Characteristics<br/>
Well matched, with a higher prevalence of coronary artery disease and statin use in the lenient-control group.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Randomly assigned to either lenient rate-control strategy (resting heart rate &lt;110 beats per minute) or strict rate-control strategy (resting heart rate &lt;80 beats per minute and heart rate during moderate exercise &lt;110 beats per minute).<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome<br/>
Composite of death from cardiovascular causes, hospitalization for heart failure, and stroke, systemic embolism, bleeding, and life-threatening arrhythmic events: 12.9% in lenient-control group vs. 14.9% in strict-control group at 3 years (P&lt;0.001 for noninferiority).<br/>
<br/>
Secondary Outcomes<br/>
Similar frequencies of the components of the primary outcome between groups.<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
Study population may be considered low-risk, physically active patients, potentially limiting generalizability.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported by the Netherlands Heart Foundation, AstraZeneca, Biotronik, Boehringer Ingelheim, Boston Scientific, Medtronic, Roche, and Sanofi Aventis France.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
The original publication and supplementary material can be accessed through The New England Journal of Medicine website.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
